Pharmaceutical compositions and the treatment of overactive bladder
The present invention relates to methods of treating overactive bladder and the symptoms associated therewith, for example, urinary urgency, frequency of micturitions, nocturia, and urgency urinary incontinence. One treatment method according to the present invention comprises treatment with the beta-3 adrenergic receptor agonist solabegron. Another treatment combination according to the invention comprises solabegron, and a muscarinic receptor antagonist which results in a synergistic effect on the symptoms associated with OAB.
1. A method of treating overactive bladder in a human in need thereof comprising orally administering to the human a therapeutically effective amount of solabegron or a pharmaceutically-acceptable salt thereof, wherein treating overactive bladder is treating an increase in urinary urgency.
2. The method of claim 1 , wherein treating an increase in urinary urgency is measured by a percent change from baseline in urinary urgency episodes.
3. The method of claim 1 , wherein treating an increase in urinary urgency results in a decrease in urinary urgency.
4. The method of claim 1 , wherein the solabegron or the pharmaceutically-acceptable salt thereof is in a pharmaceutical composition comprising one or more pharmaceutically-acceptable carriers, diluents, or excipients.
5. The method of claim 4 , wherein the pharmaceutical composition is selected from a capsule, a tablet, a powder, a granule, a solution, a suspension, an edible foam, an edible whip, an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
6. The method of claim 4 , wherein the pharmaceutical composition is a tablet.
7. The method of claim 1 , wherein the pharmaceutically-acceptable salt is the hydrochloride salt.
8. The method of claim 1 further comprising treating one or more of symptoms of overactive bladder selected from the group consisting of micturition frequency, nocturia, urinary incontinence, and a combination thereof.
9. A method of treating overactive bladder in a human in need thereof consisting of orally administering to the human a therapeutically effective amount of solabegron or a pharmaceutically-acceptable salt thereof, wherein treating overactive bladder is treating an increase in urinary urgency.
10. The method of claim 9 , wherein treating an increase in urinary urgency is measured by a percent change from baseline in urinary urgency episodes.
11. The method of claim 9 , wherein treating an increase in urinary urgency results in a decrease in urinary urgency.
12. The method of claim 9 , wherein the solabegron or the pharmaceutically-acceptable salt thereof is in a pharmaceutical composition comprising one or more pharmaceutically-acceptable carriers, diluents, or excipients.
13. The method of claim 12 , wherein the pharmaceutical composition is selected from a capsule, a tablet, a powder, a granule, a solution, a suspension, an edible foam, an edible whip, an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
14. The method of claim 12 , wherein the pharmaceutical composition is a tablet.
15. The method of claim 9 , wherein the pharmaceutically-acceptable salt is the hydrochloride salt.
16. The method of claim 9 further comprising treating one or more of symptoms of overactive bladder selected from the group consisting of micturition frequency, nocturia, urinary incontinence, and a combination thereof.